Shopping Cart

Your shopping cart is currently empty

D-GsMTx4 TFA

Name: D-GsMTx4 TFA
Brand: TargetMol
SKU: T37697L
Price: 163 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Hot

Synonyms:

Catalog No. T37697L Copy Product Info

Purity: 99.65%

😃Good

Hot

D-GsMTx4 TFA belongs to natural products and is a TRPC1/6 and Piezo2 channel inhibitor with high selectivity and cell permeability, inhibiting Ca2+ influx and the mTOR pathway. This compound is used in research on myocardial infarction, chronic pain, and pulmonary fibrosis.

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
100 μg	$163	In Stock	In Stock
500 μg	$438	In Stock	In Stock
1 mg	$592	In Stock	In Stock
5 mg	$1,160	In Stock	In Stock
10 mg	$1,670	In Stock	In Stock
25 mg	$2,490	In Stock	In Stock
50 mg	$3,360	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.65%

Appearance:Solid

Color:White

Resource Download

COA HPLC MS

Product Introduction

Bioactivity

Description	D-GsMTx4 TFA belongs to natural products and is a TRPC1/6 and Piezo2 channel inhibitor with high selectivity and cell permeability, inhibiting Ca2+ influx and the mTOR pathway. This compound is used in research on myocardial infarction, chronic pain, and pulmonary fibrosis.
In vitro	Methods: In isolated mouse cardiomyocytes, D-GsMTx4 TFA (10 μM) was incubated for 15 minutes, followed by assessment via contractility measurement and Fura-2AM calcium imaging. Results: It significantly improved hypoxia-induced contractile dysfunction, restored calcium transient peak and kinetics, and inhibited activation of the JNK/c-Jun apoptotic signaling pathway. [1] Methods: In bEnd.3 mouse brain microvascular endothelial cells, pretreatment with D-GsMTx4 TFA (0.1–10 μM) for 24 hours was performed before OGD/R injury. Results: CCK-8 assay showed significantly improved cell viability in the 10 μM group; wound healing and Transwell experiments demonstrated markedly enhanced cell migration capacity at this concentration.[2]
In vivo	Methods: In a C57BL/6J mouse myocardial ischemia-reperfusion model, D-GsMTx4 TFA was administered via tail vein injection (0.1, 1, 10 mg/kg) 20 minutes before ischemia or via intraperitoneal injection (50 mg/kg/day) for 2 days before surgery (vehicle: saline). Results: Intravenous injection of 1 mg/kg reduced infarct area by approximately 40%, improved cardiac function, and significantly decreased the incidence of premature ventricular contractions during early reperfusion. [1] Methods: In a male SD rat chronic cerebral hypoperfusion model induced by bilateral common carotid artery ligation, D-GsMTx4 TFA (0.1, 1, 10 ng/kg) was administered once daily via lateral ventricle cannulation from 3 days before surgery until 28 days after surgery. Results: The 10 ng/kg dose significantly improved cognitive function, reduced brain water content and Evans blue extravasation, and upregulated the expression of tight junction proteins Claudin-1, Occludin, and ZO-1. [2] Methods: In isolated mouse bladder preparations, D-GsMTx4 TFA (1 μM, dissolved in KBS) was administered via bath application during the filling phase to examine its effects on soluble nucleotidase release. Results: Combined use of GsMTx4 and D-GsMTx4 significantly increased stretch-induced eATP degradation and eADP, eAMP, and eADO production, indicating that inhibition of PIEZO channels relieves the restriction on enzyme release. [3]

Chemical Properties

Molecular Weight	4216.93
Formula	C₁₈₇H₂₇₉F₃N₄₈O₄₈S₆
Smiles	[H]NCC(N[C@@H](CS)C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC2=CNC3=C2C=CC=C3)C(N[C@@H](CC4=CNC5=C4C=CC=C5)C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N6CCC[C@H]6C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@@H](CS)C(N[C@@H](CS)C(N[C@H](C(N7CCC[C@H]7C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC8=CC=CC=C8)C(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N[C@@H](CC9=CC=CC=C9)C(N[C@H](C(N[C@@H](CC%10=CC=CC=C%10)C(O)=O)=O)CO)=O)=O)CC(N)=O)=O)=O)CC(C)C)=O)CCCCN)=O)=O)CC(C)C)=O)CCCCN)=O)CO)=O)=O)CCCCN)=O)CC(C)C)=O)CCCCN)=O)=O)CCCNC(N)=N)=O)=O)=O)CCCCN)=O)=O)=O)CC(N)=O)=O)=O)CC(N)=O)=O)=O)CCCCN)=O)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)=O.OC(C(F)(F)F)=O
Relative Density.	no data available
Sequence	Gly-Cys-Leu-Glu-Phe-Trp-Trp-Lys-Cys-Asn-Pro-Asn-Asp-Asp-Lys-Cys-Cys-Arg-Pro-Lys-Leu-Lys-Cys-Ser-Lys-Leu-Phe-Lys-Leu-Cys-Asn-Phe-Ser-Phe-NH₂ (Disulfide bridge:Cys2-Cys17;Cys9-Cys23;Cys16-Cys30)
Sequence Short	GCLEFWWKCNPNDDKCCRPKLKCSKLFKLCNFSF

Storage & Solubility Information

Storage

Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 250 mg/mL (59.28 mM)

H2O: 36 mg/mL (8.54 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 3.3 mg/mL (0.78 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.2371 mL	1.1857 mL	2.3714 mL	11.8570 mL
5 mM	0.0474 mL	0.2371 mL	0.4743 mL	2.3714 mL

DMSO

	1mg	5mg	10mg	50mg
10 mM	0.0237 mL	0.1186 mL	0.2371 mL	1.1857 mL
20 mM	0.0119 mL	0.0593 mL	0.1186 mL	0.5928 mL
50 mM	0.0047 mL	0.0237 mL	0.0474 mL	0.2371 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.